Cabaletta Bio

CABA

Market cap $353M

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s (“Cabaletta Bio” or “Cabaletta”) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug product manufactured on Cellares' Cell Shuttle™ automated manufacturing platform. The administration of an autologous cell therapy, which met all release.

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA.

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY.

Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA's prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development.

Here is how Cabaletta Bio, Inc. (CABA) and Celcuity, Inc. (CELC) have performed compared to their sector so far this year.

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio's (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares' Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing. The clearance allows for the clinical manufacturing and release of rese-cel using Cellares' fully a.